Last reviewed · How we verify
ETOPOSIDE
ETOPOSIDE is a Topoisomerase Inhibitor [EPC] drug. It is currently FDA-approved (first approved 1983) for Refractory Testicular Tumors, Small Cell Lung Cancer.
At a glance
| Generic name | ETOPOSIDE |
|---|---|
| Drug class | Topoisomerase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Refractory Testicular Tumors
- Small Cell Lung Cancer
Boxed warnings
- WARNINGS Etoposide injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.
Common side effects
- Leukopenia (less than 1,000 WBC/mm 3)
- Leukopenia (less than 4,000 WBC/mm 3)
- Thrombocytopenia (less than 50,000 platelets/mm 3)
- Thrombocytopenia (less than 100,000 platelets/mm 3)
- Anemia
- Nausea and vomiting
- Abdominal pain
- Anorexia
- Diarrhea
- Stomatitis
- Hepatic
- Alopecia
Drug interactions
- cyclosporin A
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETOPOSIDE CI brief — competitive landscape report
- ETOPOSIDE updates RSS · CI watch RSS
Frequently asked questions about ETOPOSIDE
What is ETOPOSIDE?
ETOPOSIDE is a Topoisomerase Inhibitor [EPC] drug, indicated for Refractory Testicular Tumors, Small Cell Lung Cancer.
What is ETOPOSIDE used for?
ETOPOSIDE is indicated for Refractory Testicular Tumors, Small Cell Lung Cancer.
What drug class is ETOPOSIDE in?
ETOPOSIDE belongs to the Topoisomerase Inhibitor [EPC] class. See all Topoisomerase Inhibitor [EPC] drugs at /class/topoisomerase-inhibitor-epc.
When was ETOPOSIDE approved?
ETOPOSIDE was first approved on 1983.
What development phase is ETOPOSIDE in?
ETOPOSIDE is FDA-approved (marketed).
What are the side effects of ETOPOSIDE?
Common side effects of ETOPOSIDE include Leukopenia (less than 1,000 WBC/mm 3), Leukopenia (less than 4,000 WBC/mm 3), Thrombocytopenia (less than 50,000 platelets/mm 3), Thrombocytopenia (less than 100,000 platelets/mm 3), Anemia, Nausea and vomiting.
Related
- Drug class: All Topoisomerase Inhibitor [EPC] drugs
- Indication: Drugs for Refractory Testicular Tumors
- Indication: Drugs for Small Cell Lung Cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing